PureNano combines a machine with expert process development to obtain smaller and more consistent particle sizes for several applications including pharmaceutical and energy industries.
The PureNano Continuous Crystallizer offers research teams with new tools and methods to generate stable inhalable formulations, improve the bioavailability of antibiotics and target delivery of novel cancer treatments.
Additional applications of PureNano include multi-phase chemical reactions and process intensification.
Microfluidics president and chief executive officer Michael Ferrara said PureNano is a milestone achievement of innovation for the company and represents a revolutionary and necessary step forward in the evolution of continuous crystallization.
PureNano/MRT is a globally-patent-pending technology with active filings and applications in Australia, Canada, China, Europe, India, Israel, Japan and the US.